​Pharmaceutical products have different microbiological considerations and specifications  that are determined by the nature of the medicinal product, the method of manufacture, and the intended use of the product. Existing dosage forms are well characterised and understood, and therefore are associated with established and validated specifications, test methods and acceptance criteria. MAP products are a new delivery system and, while learnings from analogous dosage forms are important, they have some unique features that must be considered when assessing the microbiological quality and safety of the product, in terms of the risk of a clinically significant infection.

We therefore brought together a group of stakeholders to identify the pertinent features of MAP products that should be considered when assessing the risk of infection and share their expert opinions and experiences  with the scientific community. The published findings of this work can be accessed HERE (Journal of Controlled Release), and will hopefully help to inform microbiological risk assessments for emerging MAP products.